Skip to main content
Clinical Trials/NCT02048189
NCT02048189
Terminated
Phase 4

Treatment With Continuous Sub-cutaneous Insulin Infusion Via a Portable Pump Versus Discontinuous Insulin Infusion Via Multiple-injections in Type 2 Diabetes: Study of Insulin Sensitivity in the 2 Types of Treatment

Centre Hospitalier Universitaire Dijon2 sites in 1 country14 target enrollmentMarch 8, 2012

Overview

Phase
Phase 4
Intervention
LEVEMIR
Conditions
Patient With Type 2 Diabetes Treated With Insulin Using a Baseline/Bolus Strategy
Sponsor
Centre Hospitalier Universitaire Dijon
Enrollment
14
Locations
2
Primary Endpoint
Mixed measurement of insulin secretion and insulin resistance
Status
Terminated
Last Updated
2 years ago

Overview

Brief Summary

This is an open multicentre, randomized study to compare two treatment arms. One arm called "intensification of multiple injections" in which the patient will receive one supplementary injection of LEVEMIR®: that is to say 5 injections per day, and an arm called "continuous insulin infusion" via an external pump with APIDRA®.

In the pump arm: a favorable effect in terms of improved insulin sensitivity, improved metabolic equilibrium, a decrease in the area under the baseline and prandial hyperglycemia curve noted during the continuous glycemia recording; an improvement in quality of life compared with treatment using multiple injections.

Registry
clinicaltrials.gov
Start Date
March 8, 2012
End Date
February 26, 2015
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Persons who have provided written informed consent
  • Age \> 18 years
  • Patients with type 2 diabetes treated with insulin using a basal / bolus strategy for at least 6 months
  • Doses of insulin \> 0.7 U / Kg / d
  • HbA1c ≥ 7.5 %
  • Without OAD for at least 4 weeks (sulfamides, Incretines, glinides, acarbose) except Metformin
  • BMI ≥ 28.5 kg / m2
  • Diabetes diagnosed for at least 10 years
  • Patients able to monitor themselves and manage an insulin pump.

Exclusion Criteria

  • Patients treated with glitazones during the 3 months preceding inclusion
  • Patients with proliferative ischemic retinopathy not treated by laser
  • BMI \< 28.5 kg / m2
  • Presence of implantable material ( CI MRI )
  • Pacemaker ( CI MRI )
  • Pregnancy, breast feeding
  • Medically significant physical or psychiatric inability, patients under guardianship or wards of court
  • The practice of violent sports
  • Poor conditions of hygiene
  • Professional environment of extreme cold or heat.

Arms & Interventions

Intensified multiple injections

Intervention: LEVEMIR

Pumps

Intervention: APIDRA

Outcomes

Primary Outcomes

Mixed measurement of insulin secretion and insulin resistance

Time Frame: Change from baseline insulin secretion and insuline resistance at 6 month after starting the treatment

Secondary Outcomes

  • Decrease in the time spent in baseline and prandial hyperglycemia(During the 6 months following initiation of the treatment)

Study Sites (2)

Loading locations...

Similar Trials